If you make changes to this saved search, you'll find the original and new searches in your account.
Your search filters:
Nightstar Therapeutics plc
Showing 1-10 of about 21 articles.
Nightstar Therapeutics
Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders Preliminary Efficacy Data from Phase 2/3 ...
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal ...
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal ...
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal ...
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal ...
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal ...
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal ...
Nightstar Therapeutics
NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses Preliminary ...
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, United Kingdom, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Â Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare ...
Nightstar Therapeutics
Regenerative Medicine Advanced Therapy (RMAT) Designation received in June 2018 for NSR-REP1 in Choroideremia Preliminary data from Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigmentosa expected ...
Showing 1-10 of about 21 articles.
